Finemark National Bank & Trust Sells 46,639 Shares of Icon Plc $ICLR

Finemark National Bank & Trust cut its stake in shares of Icon Plc (NASDAQ:ICLR) by 94.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,615 shares of the medical research company’s stock after selling 46,639 shares during the quarter. Finemark National Bank & Trust’s holdings in Icon were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its position in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after buying an additional 56 shares in the last quarter. Spire Wealth Management lifted its stake in shares of Icon by 10.1% in the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 62 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 94 shares in the last quarter. Sierra Legacy Group boosted its holdings in shares of Icon by 2.5% during the 3rd quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock valued at $794,000 after acquiring an additional 110 shares in the last quarter. Finally, SkyView Investment Advisors LLC grew its position in Icon by 1.8% during the 2nd quarter. SkyView Investment Advisors LLC now owns 6,321 shares of the medical research company’s stock worth $914,000 after acquiring an additional 113 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Trading Up 0.1%

NASDAQ:ICLR opened at $108.27 on Tuesday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The firm’s fifty day moving average is $158.03 and its 200-day moving average is $169.82. The firm has a market cap of $8.74 billion, a P/E ratio of 14.65, a P/E/G ratio of 2.77 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a research report on Tuesday, February 17th. TD Cowen raised Icon from a “hold” rating to a “buy” rating and lowered their price objective for the company from $183.00 to $120.00 in a research note on Wednesday, February 18th. BMO Capital Markets reiterated a “market perform” rating and set a $100.00 target price on shares of Icon in a research report on Thursday, February 12th. Robert W. Baird set a $119.00 price target on shares of Icon in a research report on Friday, February 13th. Finally, Barclays raised their price target on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $157.47.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.